Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6114552 | Autoimmunity Reviews | 2012 | 5 Pages |
Abstract
Autoantibodies targeting the proliferating cell nuclear antigen (PCNA) were first described over 30Â years ago and are historically most commonly associated with systemic lupus erythematosus (SLE). The primary antigenic target is a 34Â kDa protein that is part of the DNA polymerase delta multi-protein complex. A number of diagnostic platforms have incorporated PCNA into their diagnostic assays and algorithms. However, little is known about the clinical utility of autoantibodies to PCNA, especially with novel detection systems. This review will focus on the history of the discovery of the PCNA autoantigen and the current status of the diagnostic significance of anti-PCNA and suggest future studies that are required to strengthen our understanding of their clinical utility.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Michael Mahler, Kiyomitsu Miyachi, Carol Peebles, Marvin J. Fritzler,